Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities:
Net loss	$ (32,252)	$ (39,592)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,561	3,955
Stock-based compensation	33,253	22,061
(Gain) loss on change in fair value of warrant liabilities	(38,494)	(8,627)
Amortization of premiums and accretion of discounts on available-for-sale securities	(1,409)	(2,302)
Other, net	825	939
Changes in operating assets and liabilities:
Accounts receivable	748	1,897
Prepaid expenses and other current assets	(12,471)	(4,656)
Accounts payable	3,272	(521)
Accrued expenses and other current liabilities	6,123	(554)
Unearned revenue	1,299	4,389
Other assets and liabilities	(480)	2,546
Net cash provided by (used in) operating activities	(33,025)	(20,465)
Cash flows from investing activities:
Purchases of property and equipment	(2,308)	(3,140)
Capitalized software development costs	(882)	(1,400)
Intangible asset acquisition costs	(220)	(357)
Purchases of available-for-sale securities	(320,571)	(66,619)
Maturities of available-for-sale securities	93,805	115,045
Net cash provided by (used in) investing activities	(230,176)	43,529
Cash flows from financing activities:
Proceeds from at-the-market offering, net of issuance costs	362,303
Proceeds from stock options exercised	1,213	486
Proceeds from public warrants exercised	4,702
Tax withholding receipts (payments) related to vested and released RSUs, net	516	873
Net cash provided by (used in) financing activities	368,734	1,359
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	(13)	4
Net change in cash, cash equivalents and restricted cash	105,520	24,427
Cash, cash equivalents and restricted cash at the beginning of the period	56,840	38,081
Cash, cash equivalents and restricted cash at the end of the period	162,360	62,508
Supplemental disclosures of non-cash investing and financing transactions
Property and equipment purchases in accounts payable and accrued expenses	152	3,043
Intangible asset purchases in accounts payable and accrued expenses	257	391
Operating lease right-of-use assets subject to lease liability		5,021
Noncash reclassification of warrant liabilities to equity upon exercise	10,953
Bonus settled in restricted stock units	6,969	11,443
Net share settled stock option exercises		$ 1,016
At-the-market offering issuance costs in accounts payable and accured expenses	$ 4,049